Celgene pulls EU application for anemia-drug approval

06/2/2008 | Boston Globe (tiered subscription model), The · Reuters

The European Medicines Agency has again declined to recommend approval for Celgene's Revlimid, prompting the company to withdraw its application to market the anemia drug for transfusion-dependent patients with myelodysplastic syndromes. The drugmaker said it will not abandon plans to seek approval for the indication in Europe despite the agency's negative review.

View Full Article in:

Boston Globe (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC